Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Allison Ching Yee Tso, Wee Joo Chng, Yeow Tee Goh, Melissa Ooi, Yunxin Chen, Chandramouli Nagarajan, Daryl Tan, Kiat Hoe Ong

Blood (2022) 140 (Supplement 1): 12596–12597.

https://doi.org/10.1182/blood-2022-157940

Published: 2022

Journal Articles

Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study

Blood (2021) 138 (Supplement 1): 720.

https://doi.org/10.1182/blood-2021-149331

Published: 2021

Journal Articles

Treatment Outcomes of Early-Stage Natural-Killer/T-Cell Lymphomas Treated with Chemoradiotherapy: Data from 3 Tertiary Cancer Centres in Singapore

Ya Hwee Tan, MBBS, MRCP, Siqin Zhou, MSc, Liu Xin, Soon Thye Lim, MBBS, MRCP, FAMS, Miriam Tao, MBBS, FAMS, FHKAM, FHKCP, MRCP, Daryl Tan, MBBS, MRCP, Michelle Poon, MBBS, MRCP, FRCPATH, Mohamad Farid, MBBS, MMed, MRCP, Colin Phipps Diong, Yuh Shan Lee, Shin-Yeu Ong, MD, Nicholas Francis Grigoropoulos, Kheng Wei Yeoh, MBBS, MSc, MRCP, MPH, FRCR (Clinical Oncology), Nagavalli Somasundaram, MBBS, MRCP, Eileen Yi Ling Poon, MBBS, MRCP, MMED, Jason Yongsheng Chan, MBBS, MRCP, Esther Wei Yin Chang, MD MRCP, Tiffany Tang, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 5274.

https://doi.org/10.1182/blood-2019-125085

Published: 2019

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Blood (2018) 132 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2018-99-118364

Published: 2018

Journal Articles

Whole-Genome Genomics Correlates of Response to Anti-PD1 Therapy in Relapsed/Refractory Natural Killer/T Cell Lymphoma

Jing Quan Lim, PhD, Tiffany Tang, MBBS, MRCP, Daryl Tan, MD, Yurike Laurensia, Burton Chia Kuan Hui, Bsc, Jabed Iqbal, MD, Dachuan Huang, PhD, Tammy Song, PhD, Cedric Chuan Young Ng, MSc, Huangming Hong, Rex Au-Yeung, Benjamin Mow, MD, Qichun Cai, MD, LM Poon, Yok-Lam Kwong, Jin-Xin BEI, PhD, Tongyu Lin, Soon Thye Lim, Choon Kiat Ong, PhD

Blood (2018) 132 (Supplement 1): 2915.

https://doi.org/10.1182/blood-2018-99-110900

Published: 2018

Journal Articles

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase

Yok-Lam Kwong, Thomas S. Y. Chan, Daryl Tan, Seok Jin Kim, Li-Mei Poon, Benjamin Mow, Pek-Lan Khong, Florence Loong, Rex Au-Yeung, Jabed Iqbal, Colin Phipps, Eric Tse

Blood (2017) 129 (17): 2437–2442.

https://doi.org/10.1182/blood-2016-12-756841

Published: 2017

Includes: Supplemental data

Journal Articles

Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort

Colin Phipps, MBBS, MRCP, FRCPath, Yuh Shan Lee, MBBS, MRCP, FRCPath, Chandramouli Nagarajan, MBBS, MD MRCP, Yunxin Chen, MBBS, MRCP, FRCPath, Allan ZK Goh, Lay Poh Khoo, BSc, Kevin Tay, MD, Miriam Tao, MD, Richard Quek, Tiffany Tang, MD, Mohamad Farid, MD, Soon Thye Lim, MBBS, MRCP, Sathish Kumar Gopalakrishnan, FRCPath, Nicholas F Grigoropoulos, MRCP, FRCPath, Yvonne Loh, MBBS, MRCP, Daryl Tan, MBBS, MRCP, William YK Hwang, MBBS, MRCP, FRCP, Yeow Tee Goh, MD

Blood (2016) 128 (22): 1871.

https://doi.org/10.1182/blood.V128.22.1871.1871

Published: 2016

Journal Articles

Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group

Sathish Kumar Gopalakrishnan, FRCPath, Shin-Yeu Ong, MD MRCP, MSE, Seok Jin Kim, Hae Su Kim, MD, Ji Yun Lee, Sung Hee Lim, Yunxin Chen, MBBS, MRCP, FRCPath, Sanjay De Mel, BSc, FRCPath, MRCP,, Melissa G. Ooi, Shilpa Surendran, MBBS, Adeline Lin, Daryl Tan, MBBS, MRCP, Brian G M Durie, Wee Joo Chng, MB ChB, MRCP, PhD, Kihyun Kim, MD PhD

Blood (2016) 128 (22): 4650.

https://doi.org/10.1182/blood.V128.22.4650.4650

Published: 2016

Journal Articles

A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)

Yeow-Tee Goh, MBBS,MMed, William YK Hwang, FRCP, FAMS, MMed, MRCP, MBBS, Colin Phipps Diong, Yap chun Hsien, bsc, Kevin Tay, MD, Soon Thye Lim, MBBS, MRCP, Yuh Shan Lee, MBBS, MRCP, Soo Chin Ng, MD, S Fadilah, MBBS, Won Seog Kim, Daryl Tan, MD

Blood (2014) 124 (21): 503.

https://doi.org/10.1182/blood.V124.21.503.503

Published: 2014

Journal Articles

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

Daryl Tan, Sandra J. Horning, Richard T. Hoppe, Ronald Levy, Saul A. Rosenberg, Bronislava M. Sigal, Roger A. Warnke, Yasodha Natkunam, Summer S. Han, Alan Yuen, Sylvia K. Plevritis, Ranjana H. Advani

Blood (2013) 122 (6): 981–987.

https://doi.org/10.1182/blood-2013-03-491514

Published: 2013

Includes: Supplemental data

Journal Articles

Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study

Blood (2012) 120 (21): 5035.

https://doi.org/10.1182/blood.V120.21.5035.5035

Published: 2012

Journal Articles

Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response

Daryl Tan, MD, William YK Hwang, MBBS, FRCP, FAMS, Colin Phipps Diong, Wee Lee Goh, BSC, Lionel K.Y See, BSc, Yiong Huak Chan, PHD, Soon Thye Lim, MRCP MBBS, Soo Chin Ng, MBBS MRCP, S Fadilah, MBBS, Soo-Yong Tan, MBBS, FRCPath, DPhil, Won Seog Kim, MD, Yeow Tee Goh, MD

Blood (2012) 120 (21): 3669.

https://doi.org/10.1182/blood.V120.21.3669.3669

Published: 2012

Journal Articles

Gene Expression Profiling Identifies the JAK/STAT and NFκB Pathways to Be Important in Peripheral T-Cell Lymphomas and Natural-Killer T-Cell Lymphomas

Tiffany Tang, MBBS, MRCP, George Allen, Ghee Chong Koo, PhD, Kevin Tay, MD, Daryl Tan, MBBS, MRCP, Richard Quek, MBBS, MRCP, Miriam Tao, MBBS, MRCP, Soo Yong Tan, MBBS, MRCPath, Bin Tean Teh, MD, PhD, Soon Thye Lim, MBBS, MRCP

Blood (2011) 118 (21): 2658.

https://doi.org/10.1182/blood.V118.21.2658.2658

Published: 2011

Journal Articles

Dual Translocation Is An Independent Poor Prognostic Factor in Diffuse Large B-Cell Lymphoma,

Kevin Tay, MD, Gillianne Lai, Elaine J Chua, Whee Sze Ong, Tiffany Tang, MBBS, MRCP, Richard Quek, MBBS, MRCP, Daryl Tan, MBBS, MRCP, Leonard Tan, MBBS, MRCPath, Miriam Tao, MBBS, MRCP, Soo Yong Tan, MBBS, MRCPath, Soon Thye Lim, MBBS, MRCP

Blood (2011) 118 (21): 3683.

https://doi.org/10.1182/blood.V118.21.3683.3683

Published: 2011

Journal Articles

Should Intensive Chemotherapy Be Required for All Mantle Cell Lymphoma Patients

Zhen Tang Lao, MBBS, MRCP, Kathleen Khoo, Jasmine Koh, Whee Sze Ong, Tiffany Tang, MBBS, MRCP, Richard Quek, MBBS, MRCP, Leonard Tan, MBBS, MRCPath, Daryl Tan, MBBS, MRCP, Miriam Tao, MBBS, MRCP, Soo Yong Tan, MBBS, MRCPath, Soon Thye Lim, MBBS, MRCP, Kevin Tay, MD

Blood (2011) 118 (21): 5188.

https://doi.org/10.1182/blood.V118.21.5188.5188

Published: 2011

Journal Articles

Follicular Lymphoma with Diffuse Large B-Cell Component At Initial Diagnosis Appears to Be Associated with a Loss of BCL2 Translocation and Inferior Progression Free Survival

Kevin Tay, MD, Yee Siang Shew, MBBS, Yu Lin Gao, Whee Sze Ong, Tiffany Tang, MBBS, MRCP, Richard Quek, MBBS, MRCP, Daryl Tan, MBBS, MRCP, Leonard Tan, MBBS, MRCPath, Miriam Tao, MBBS, MRCP, Soo Yong Tan, MBBS, MRCPath, Soon Thye Lim, MBBS, MRCP

Blood (2011) 118 (21): 1577.

https://doi.org/10.1182/blood.V118.21.1577.1577

Published: 2011

Journal Articles

Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response

Daryl Tan, MBBS, MRCP, Bernard K.C Yap, BSc, Lionel K.Y See, BSc, Grace Kam, MBBS, MRCP, Colin Phipps Diong, Yuh Shan Lee, MBBS, MRCP, Dawn Mya, MBBS, MRCP, William Hwang, MBBS, FRCP, FAMS, Yeow Tee Goh, MD

Blood (2010) 116 (21): 3056.

https://doi.org/10.1182/blood.V116.21.3056.3056

Published: 2010

Journal Articles

Risk of Hepatitis B Virus (HBV) Reactivation and the Role of Anti-Viral Prophylaxis in Multiple Myeloma Patients with HBV Infection in the Era of Novel Therapies.

Dawn Mya, MBBS, Shuting Han, Yeow Tee Goh, MBBS, Daryl Tan, MBBS, MRCP

Blood (2009) 114 (22): 3882.

https://doi.org/10.1182/blood.V114.22.3882.3882

Published: 2009

Journal Articles

Survival in Follicular Lymphoma: The Stanford Experience, 1960–2003.

Daryl Tan, MD, Saul A. Rosenberg, MD, Ronald Levy, MD, Philip Lavori, PhD, Robert Tibshirani, PhD, Richard T. Hoppe, MD, Roger Warnke, MD, Ranjana Advani, MD, Yasodha Natkunam, MD, Alan Yuen, MD, Sandra J. Horning, MD

Blood (2007) 110 (11): 3428.

https://doi.org/10.1182/blood.V110.11.3428.3428

Published: 2007

NARROW

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study

Treatment Outcomes of Early-Stage Natural-Killer/T-Cell Lymphomas Treated with Chemoradiotherapy: Data from 3 Tertiary Cancer Centres in Singapore

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Whole-Genome Genomics Correlates of Response to Anti-PD1 Therapy in Relapsed/Refractory Natural Killer/T Cell Lymphoma

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase

Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort

Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group

A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study

Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response

Gene Expression Profiling Identifies the JAK/STAT and NFκB Pathways to Be Important in Peripheral T-Cell Lymphomas and Natural-Killer T-Cell Lymphomas

Dual Translocation Is An Independent Poor Prognostic Factor in Diffuse Large B-Cell Lymphoma,

Should Intensive Chemotherapy Be Required for All Mantle Cell Lymphoma Patients

Follicular Lymphoma with Diffuse Large B-Cell Component At Initial Diagnosis Appears to Be Associated with a Loss of BCL2 Translocation and Inferior Progression Free Survival

Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response

Risk of Hepatitis B Virus (HBV) Reactivation and the Role of Anti-Viral Prophylaxis in Multiple Myeloma Patients with HBV Infection in the Era of Novel Therapies.

Survival in Follicular Lymphoma: The Stanford Experience, 1960–2003.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only